本文已被:浏览 525次 下载 340次
Received:May 20, 2021 Published Online:January 20, 2022
Received:May 20, 2021 Published Online:January 20, 2022
中文摘要: 目的 探讨领悟社会支持在系统性红斑狼疮(SLE)患者抑郁与应对方式间的中介效应。
方法 采取便利抽样的方法,选取2018年9月至2020年5月于南京中医药大学第二附属医院风湿免疫科住院治疗的285例SLE患者作为研究对象,采用一般资料调查表、领悟社会支持量表(PSSS)、抑郁自评量表(SDS)和医学应对方式问卷(MCMQ)进行调查。
结果 SLE患者抑郁与应对方式面对维度呈负相关(r=-0.503,P<0.01),与回避和屈服维度呈正相关(r=0.386,P<0.01;r=0.404,P<0.01)。领悟社会支持是SLE患者抑郁与应对方式的中介变量,其中介间接效应在应对方式的面对、回避、屈服维度上,分别占总效应的37.18%、34.81%和43.42%。
结论 SLE患者抑郁状态处于较高水平,医护人员应给予该群体更多的心理关注与支持,协助其领悟来自家庭、朋友等各方面的支持,促进其积极应对疾病,改善健康状态。
Abstract:Objective To explore the mediating effect of perceived social support on depression and coping style in patients with systemic lupus erythematosus(SLE).
Methods By convenient sampling, 285 SLE inpatients in the Second Affiliated Hospital of Nanjing University of Chinese Medcine from September 2018 to May 2020 were selected as the research objects. A survey was performed on them using general information questionnaire, perceived social support scale (PSSS),self-rating depression scale (SDS) and medical coping modes questionnaire (MCMQ).
Results Depression in SLE patients was negatively correlated with the facing dimension of coping style (r=-0.503, P<0.01) and positively correlated with the dimension of avoidance and submission (r=0.386, P<0.01;r=0.404, P<0.01). Perceived social support was an intermediary variable between depression and coping styles in SLE patients. The indirect effects accounted for 37.18%, 34.81% and 43.42% of the total effects in the dimensions of facing, avoidance and yield of coping styles, respectively.
Conclusions SLE patients have a relatively high level of depression. Medical staff should be give this group more psychological attention and support to help them understand the supports from family, friends and other aspects, and promote their active respond to the disease and improve their health status.
keywords: Systemic lupus erythematosus Perceiving social support Depression Coping style Mediating role
文章编号: 中图分类号:R395 文献标志码:B
基金项目:江苏省中医药科技发展项目(YB2020025)
引用文本: